Viread, Tenofovir News

SUMMARY: French Biopharmaceutical company Cytheris SA announced this week that it has started enrolling participants in a Phase 1/2a clinical trial of interleukin 7 , a immune modulator intended to stimulate immune response against hepatitis B virus .

Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials Article Date: 08 Dec 2009 Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the ...

SUMMARY: Simvastatin , a medication used to lower blood cholesterol, had a synergistic effect against hepatitis B virus when combined with antiviral drugs in a laboratory study, researchers reported last month at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

Countries should phase out the use of Stavudine, the most widespread antiretroviral, because of "long-term, irreversible" side-effects in HIV patients including wasting and a nerve disorder, the World Health Organization said on Monday.

China will provide two imported HIV drugs to patients who develop resistance to cheaper, domestic alternatives, state media said on Monday, going some way to meeting a key demand of AIDS treatment activists.

Long-term HIV treatment has not caused a deterioration in kidney function among French patients, investigators report in the December 15th edition of Clinical Infectious Diseases .

Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread for the treatment of chronic hepatitis B infection in adults in five countries in Asia.

Tenofovir Produces Good HBV Suppression in Chronic Hepatitis B Patients with Resistance to Adefovir SUMMARY: Nucleoside/nucleotide analogs are highly effective against HBV , but the virus can evolve to become resistant to the drugs, especially when used as monotherapy.

ASSERT Study Adds to Comparative Data on Abacavir versus Tenofovir SUMMARY: HIV patients receiving antiretroviral regimens containing tenofovir may be slightly less likely to experience virological failure than those taking abacavir , according to data from the ASSERT trial presented last week at the 12th European AIDS Conference .

A large proportion of HIV-positive men have low bone mineral density, Australian researchers report in the December 1st edition of the Journal of Infectious Diseases .

Entecavir and Tenofovir Rescue Therapy for Chronic Hepatitis B Patients with Advanced Fibrosis and Prior Treatment Failure SUMMARY: A "rescue therapy" regimen combining entecavir and tenofovir is safe and effective for chronic hepatitis B patients with advanced liver disease who have experienced past treatment failure or developed extensive drug ...

Tenofovir Suppresses HBV Viral Load Long-term in HIV/HBV Coinfected Patients, but Kidney Function May Decline SUMMARY: HIV/HBV coinfected individuals treated with agents that are dually active against both virus experience rapid suppression of hepatitis B virus , and about 15% of those taking tenofovir plus emtricitabine achieve hepatitis B "e" ...

Gilead Sciences, Inc. today announced the presentation of three-year open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection.

In 2006, Gilead took a gamble, believing the short-term costs incurred through the acquisitions of Corus Pharma, Myogen and Raylo Chemicals would lead to long-term growth for the company.

The U.S. National Institutes of Health is sponsored a large trial to explore whether the antiretroviral agents tenofovir and emtricitabine , the components of the Truvada coformulation), can prevent HIV infection in women when used in a vaginal gel or taken as once-daily oral tablets.

The American Association for the Study of Liver Diseases published a revised version of its " Practice Guidelines for Management of Chronic Hepatitis B " in the September 2009 issue of Hepatology .

The material posted on HIV and Hepatitis.com about the 49th ICAAC is not approved by the American Society for Microbiology Resistance to Hepatitis B Drugs is Common among HIV-HBV Coinfected Patients Receiving Lamivudine-containing ART without Tenofovir Resistance to the hepatitis B drugs adefovir , entecavir , and telbivudine is common among ...

India's patent office has rejected applications from two U.S. drug companies for patent protection for two HIV/AIDS drugs: tenofovir, a first-line AIDS treatment that Gilead Sciences sells under the name Viread, and darunavir, a second-line treatment sold by Tibotec Pharmaceuticals as Prezista.

Cidofovir has been officially approved for the treatment of cytomegalovirus retinitis in AIDS patients, tenofovir disoproxil fumarate for the treatment of HIV infections and adefovir dipivoxil for the treatment of chronic hepatitis B. @article{citeulike:5756963, abstract = {The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: ...

HIV positive people coinfected with hepatitis B virus respond as well to combination antiretroviral therapy as individuals with HIV alone, but they are more likely to die due to non-AIDS-related causes, according to a study published in the September 10, 2009 issue of AIDS .